AU2014385276B2 - Isothiazole derivatives as GPR120 agonists for the treatment of Type II diabetes - Google Patents

Isothiazole derivatives as GPR120 agonists for the treatment of Type II diabetes Download PDF

Info

Publication number
AU2014385276B2
AU2014385276B2 AU2014385276A AU2014385276A AU2014385276B2 AU 2014385276 B2 AU2014385276 B2 AU 2014385276B2 AU 2014385276 A AU2014385276 A AU 2014385276A AU 2014385276 A AU2014385276 A AU 2014385276A AU 2014385276 B2 AU2014385276 B2 AU 2014385276B2
Authority
AU
Australia
Prior art keywords
methoxy
trifluoromethyl
chloro
phenyl
fluoro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014385276A
Other languages
English (en)
Other versions
AU2014385276A1 (en
Inventor
Carl R. Illig
Mark R. Player
Xuqing Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2014385276A1 publication Critical patent/AU2014385276A1/en
Application granted granted Critical
Publication of AU2014385276B2 publication Critical patent/AU2014385276B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D419/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2014385276A 2014-03-07 2014-03-07 Isothiazole derivatives as GPR120 agonists for the treatment of Type II diabetes Ceased AU2014385276B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/021775 WO2015134039A1 (en) 2014-03-07 2014-03-07 Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes

Publications (2)

Publication Number Publication Date
AU2014385276A1 AU2014385276A1 (en) 2016-09-01
AU2014385276B2 true AU2014385276B2 (en) 2019-01-17

Family

ID=50391464

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014385276A Ceased AU2014385276B2 (en) 2014-03-07 2014-03-07 Isothiazole derivatives as GPR120 agonists for the treatment of Type II diabetes

Country Status (8)

Country Link
EP (2) EP3114123B1 (https=)
JP (1) JP6303031B2 (https=)
CN (1) CN106414434B (https=)
AU (1) AU2014385276B2 (https=)
CA (1) CA2941445A1 (https=)
ES (2) ES2887011T3 (https=)
MX (1) MX367852B (https=)
WO (1) WO2015134039A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2944572T3 (es) 2016-03-15 2023-06-22 Univ London Queen Mary Procedimiento de tratamiento de la obesidad
JP6809278B2 (ja) * 2017-02-17 2021-01-06 Jnc株式会社 重合性液晶化合物、重合性液晶組成物および液晶重合膜
JP2021517142A (ja) 2018-03-15 2021-07-15 アクザム ソシエタ ペル アチオニ 置換ピラゾールffa4/gpr120受容体作動薬
CN118040044B (zh) * 2023-11-07 2024-09-13 南昌大学 一种电解液与锂离子电池

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999011255A1 (en) * 1997-08-28 1999-03-11 Ono Pharmaceutical Co., Ltd. Peroxisome proliferator-activated receptor controllers
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
GB0405033D0 (en) * 2004-03-05 2004-04-07 Karobio Ab Novel pharmaceutical compositions
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
CN105209446A (zh) * 2013-03-14 2015-12-30 詹森药业有限公司 用于治疗ii型糖尿病的gpr120激动剂

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010048207A2 (en) * 2008-10-21 2010-04-29 Metabolex, Inc. Aryl gpr120 receptor agonists and uses thereof

Also Published As

Publication number Publication date
ES2887011T3 (es) 2021-12-21
CN106414434B (zh) 2019-12-31
EP3409671B1 (en) 2021-07-21
JP6303031B2 (ja) 2018-03-28
MX2016011630A (es) 2016-11-29
JP2017507189A (ja) 2017-03-16
EP3114123B1 (en) 2018-04-25
AU2014385276A1 (en) 2016-09-01
EP3409671A1 (en) 2018-12-05
CA2941445A1 (en) 2015-09-11
ES2673578T3 (es) 2018-06-22
WO2015134039A1 (en) 2015-09-11
EP3114123A1 (en) 2017-01-11
MX367852B (es) 2019-09-09
CN106414434A (zh) 2017-02-15

Similar Documents

Publication Publication Date Title
AU2014241390B2 (en) GPR120 agonists for the treatment of type II diabetes
JP6853619B2 (ja) シアノトリアゾール化合物の医薬用途
RU2527948C2 (ru) Новый агонист бета рецептора тиреоидного гормона
JP5043105B2 (ja) 有機化合物
US9067898B1 (en) Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
JP2017522277A (ja) 代謝型グルタミン酸受容体の負のアロステリックモジュレーター(nams)とその使用
JP2017530986A (ja) 2型糖尿病治療のためのgpr40アゴニストとしての置換ベンゾチオフェニル誘導体
WO2017180571A1 (en) Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
AU2014385276B2 (en) Isothiazole derivatives as GPR120 agonists for the treatment of Type II diabetes
AU2019293727B2 (en) Novel LXR modulators with bicyclic core moiety
KR102372599B1 (ko) Rxr 아고니스트로서의 치환 바이시클릭 헤테로아릴 화합물
KR20240072145A (ko) 트리아졸론 화합물 및 이의 의학적 용도
JPWO2012081570A1 (ja) ラクタム化合物又はその塩及びppar活性化剤
EP2521727B1 (fr) Nouveaux dérivés pyrrolopyridine benzoïques et leur utilisation pour le traitement de la maladie de parkinson
KR20080032155A (ko) 페록시좀 증식제 활성화 수용체 δ 의 활성화제
HK40005165A (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
HK40005165B (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
HK1233634A1 (en) Isothiazole derivatives as gpr120 agonists for the treatment of type ii diabetes
HK1233634B (zh) 异噻唑衍生物作为用於治疗ii型糖尿病的gpr120激动剂

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired